Ning Cui1, Xiao-Lei Bao2, Zhen-Dong Yang1, Qing-Bin Lu3, Chun-Yan Hu4, Li-Yuan Wang5, Bing-Jun Wang1, Hong-Yu Wang5, Kun Liu4, Chun Yuan1, Xue-Juan Fan1, Zhen Wang1, Lan Zhang1, Xiao-Ai Zhang4, Liang-Ping Hu2, Wei Liu6, Wu-Chun Cao7. 1. The 154 Hospital, People's Liberation Army, Xinyang 464000, PR China. 2. Consulting Center of Biomedical Statistics, Academy of Military Medical Sciences, Beijing 100850, PR China. 3. School of Public Health, Peking University, Beijing 100191, PR China. 4. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, PR China. 5. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, PR China; Graduate School of Anhui Medical University, Hefei, PR China. 6. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, PR China. Electronic address: lwbime@163.com. 7. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, PR China. Electronic address: caowc@bmi.ac.cn.
Abstract
BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease of which the clinical progression and factors related to death are still unclear. OBJECTIVE: To identify the clinical progression of SFTS and explore predictors of fatal outcome throughout the disease progress. STUDY DESIGN: A prospective study was performed in a general hospital located in Xinyang city during 2011-2013. Confirmed SFTS patients were recruited and laboratory parameters that were commonly evaluated in clinical practice were collected. The clinical progression was determined based on analysis of dynamic profiles and Friedman's test. At each clinical stage, the laboratory features that could be used to predict fatal outcome of SFTS patients were identified by stepwise discriminant analysis. RESULTS: Totally 257 survivors and 54 deceased SFTS patients were recruited and the data of 11 clinical and laboratory parameters along their entire disease course were consecutively collected. Three clinical stages (day 1-5 post onset, day 6-11 post onset and day 12 to hospital discharge) were determined based on distinct clinical parameters evaluations. Multivariate discriminant analysis at each clinical stage disclosed the indicators of the fatal outcome as decreased platelet counts at early stage, older age and increased AST level at middle stage, and decreased lymphocyte percentage and increased LDH level at late stage. CONCLUSIONS: The significant indicators at three clinical stages could be used to assist identifying the patients with high risk of death. This knowledge might help to perform supportive treatment and avoid fatality.
BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease of which the clinical progression and factors related to death are still unclear. OBJECTIVE: To identify the clinical progression of SFTS and explore predictors of fatal outcome throughout the disease progress. STUDY DESIGN: A prospective study was performed in a general hospital located in Xinyang city during 2011-2013. Confirmed SFTS patients were recruited and laboratory parameters that were commonly evaluated in clinical practice were collected. The clinical progression was determined based on analysis of dynamic profiles and Friedman's test. At each clinical stage, the laboratory features that could be used to predict fatal outcome of SFTS patients were identified by stepwise discriminant analysis. RESULTS: Totally 257 survivors and 54 deceased SFTS patients were recruited and the data of 11 clinical and laboratory parameters along their entire disease course were consecutively collected. Three clinical stages (day 1-5 post onset, day 6-11 post onset and day 12 to hospital discharge) were determined based on distinct clinical parameters evaluations. Multivariate discriminant analysis at each clinical stage disclosed the indicators of the fatal outcome as decreased platelet counts at early stage, older age and increased AST level at middle stage, and decreased lymphocyte percentage and increased LDH level at late stage. CONCLUSIONS: The significant indicators at three clinical stages could be used to assist identifying the patients with high risk of death. This knowledge might help to perform supportive treatment and avoid fatality.
Authors: Herwati Dualis; Abraham Chin Zefong; Lim Kai Joo; Narinderjeet Kaur Dadar Singh; Syed Sharizman Syed Abdul Rahim; Richard Avoi; Mohammad Saffree Jeffree; Mohd Rohaizat Hassan; Mohd Yusof Ibrahim; Azizan Omar Journal: Ann Med Surg (Lond) Date: 2021-06-11